IBAB Ion Beam Applications SA

IBA – Transparency Notification

IBA – Transparency Notification

 (Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings)

Louvain-la-Neuve, Belgium, May 28, 2020, 17.30

Summary of the notification

IBA (Ion Beam Application), the world’s leading provider of proton therapy solutions for the treatment of cancer, received a transparency notification dated May 19, 2020, from which it follows that, following the introduction of statutory thresholds on April 30, 2020, the University Catholique de Louvain, including the voting rights of its subsidiary Sopartec SA, now holds 2.71% of the voting rights in the company. It thus crossed upwards the 2% participation threshold.

Content of the notification

  • Reason for the notification: Introduction of statutory thresholds
  • Notification by : A parent undertaking or a controlling person
  • Persons subject to the notification requirement:

    Université Catholique de Louvain (UCLouvain), Place d’l’Université 1, 1348 Louvain-la-Neuve

    Sopartec SA, Place d’l’Université 1, 1348 Louvain-la-Neuve
  • Date on which the threshold is crossed: 30/04/2020
  • Threshold crossed (in %): 2%
  • Denominator: 38 085 047
  • Notified details: (extract of the received notification form) 
A) Voting rightsPrevious notificationAfter the transaction 
 # of voting rights# of voting rights% of voting rights 
Holders of voting rights Linked to securitiesNot linked to the securitiesLinked to securitiesNot linked to the securities 
UCLouvain426.885853.77002.24%0.00% 
Sopartec SA403.049180.00000.47%0.00% 
Subtotal829.9341.033.770 2.71%  
 TOTAL1.033.77002.71%0,00% 
       
B) Equivalent financial instrumentsAfter the transaction
Holder of equivalent financial instruments Type of financial instrumentExpiration dateExercise period or date# of voting rights that may be acquired if the instrument is exercised% of voting rightsSettlement
       
 TOTAL 00.00% 
       
 TOTAL (A & B)  # of voting rights%of voting rights 
    1.033.7702.71% 
  • Full chain of controlled undertakings through which the holding is effectively held

Sopartec SA is a subsidiary of UCLouvain (100% minus one share).

  • Additional Information

Passive crossing following the introduction of the loyalty vote and new thresholds in the Issuer's articles of association.

Reminder of the legal status of UCLouvain: legal person under private law pursuing an aim of public utility and enjoying civil personality under a law of 12 August 1911 modified by a law of 28 May 1970.

For further information, please contact:

IBA

Elodie Jaumain

Paralegal

About IBA

IBA (Ion Beam Applications) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at:

 

 

Attachment

EN
28/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Heineken: No respite / IBA: Attractive €15-20m acquisition in radio pharma.

Guy Sips ... (+8)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Michiel Declercq
  • Thibault Leneeuw
  • Wim Lewi

Morning Notes : BAR BB, COFB BB, FAGR BB, GLPG NA, IBAB BB, DEME BB, N...

: BAR BB, COFB BB, FAGR BB, GLPG NA, IBAB BB, DEME BB, NXFIL NA, ENRGY BB

 PRESS RELEASE

IBA acquires ORA expanding its strategic leadership in Nuclear Medicin...

IBA acquires ORA expanding its strategic leadership in Nuclear Medicine Louvain-La-Neuve, Belgium, 19 December 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, acquires ORA, a global trailblazer in radiochemistry based in Belgium. This acquisition emphasizes IBA’s long-term commitment to the fast-developing and promising field of nuclear medicine. It reinforces IBA’s position at the forefront of innovation in precision oncology enabling for better diagnostic and more personalized patient...

 PRESS RELEASE

Avec l’acquisition d’ORA, IBA renforce son leadership stratégique en m...

Avec l’acquisition d’ORA, IBA renforce son leadership stratégique en médecine nucléaire Louvain-la-Neuve, Belgique, le 19 décembre 2025 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules et acteur de premier plan en médecine nucléaire, acquiert ORA, pionnier mondial de la radiochimie, basé en Belgique. Cette acquisition illustre l'engagement à long terme d'IBA dans le domaine en pleine expansion et à fort potentiel de la médecine nucléaire. Elle consolide la position d'IBA à l’avant-garde de l'innovation en oncologie de précision, p...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

IBA: The Lancet Journal on proton therapy new standard of care for patients with Oropharyngeal cancer. Events Calendar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch